doi: 10.1161/ATVBAHA.108.181529
© 2009 American Heart Association, Inc.
Editorials |
Getting Radical About Obesity
New Links Between Fat and Heart Disease
From the Departement für Innere Medizin, Klinik und Poliklinik für Innere Medizin, Universitätsspital Zürich, Switzerland.
Correspondence to Matthias Barton, MD, Professor, Departement für Innere Medizin, Klinik und Poliklinik für Innere Medizin, Universitë Zürich, Rämistrasse 100, CH-8091 Zürich, Switzerland. E-mail barton{at}usz.ch
Visceral obesity has become the most frequent preventable condition accounting for diseases such as hypertension and diabetes, two of the major risk factors for coronary artery disease, stroke, and chronic renal failure.1–3 Despite the awareness aiming to reduce the prevalence of obesity, the number of obese patients continues to rise and now includes even developing countries, and increasingly children are affected.4,5 In fact, if this trend continues, 26 million children in Europe will be overweight or obese by the year 2010, rising by approximately 1.3 million per year.5,6 The annual health costs related to obesity have been estimated close to 100 billion USD in the United States,7,8 illustrating the enormous economic burden the disease obesity carries.
See accompanying article in ATVB 2009;29:239–245.
What are the mechanisms contributing to the high cardiovascular risk brought about by obesity? Obesity is a low-grade inflammatory condition9 and typically characterized by increase in visceral adipose tissue. Visceral fat is both a source and target of inflammatory cytokines and growth factors, which directly may affect preadipocyte differentiation via signaling cascades implicated in cell growth such as Ras-Raf-ERK-1/2.10 Adipose tissue also contains inflammatory cells, including cytokine-producing macrophages.9 In addition, adipocytes express a fully functional NADPH oxidase system maintaining local production of reactive oxygen species,11 which in turn either work as signaling molecules or further stimulate production of growth factors implicated in adipogenesis.12,13 Previous work has investigated effects of preadipocyte differentiation on expression of Nox4,14 a component of the vascular NADPH oxidase, and Mahadev et al demonstrated that Nox4—via H2O2—regulates insulin-mediated phosphorylation of the insulin receptor and its substrate, insulin receptor substrate (IRS)-1.15 However, whether Nox4 actively takes part in adipogenesis has remained unknown.
In the present issue of Arteriosclerosis, Thrombosis, and Vascular Biology, Schröder and coworkers now provide us with a new mechanism by which Nox4 controls preadipocyte differentiation.16 These investigators found that Nox4 represents the switch between insulin-induced proliferation of preadipocytes and differentiation through activation of MAPK phosphatase-1 (MKP-1). Insulin lowers not only blood glucose by facilitating its uptake into target tissues, but is also an important regulator of adipogenesis. Schröder et al further show that insulin-mediated differentiation of preadipocytes depends on the formation of H2O2, likely derived from Nox4, either directly or through conversion from superoxide anion.17 Silencing of Nox4 gene expression attenuated insulin-induced H2O2 production. A causal role of H2O2 was further confirmed by overexpressing or supplementing cells with catalase, both of which blocked preadipocyte differentiation. Overexpression of Nox4 reduced ERK-1/2 phosphorylation and serine phosphorylation of IRS-1, which was accompanied by a concomitant increase in tyrosine phosphorylation of IRS-1, thereby promoting metabolic insulin signaling. The authors further demonstrate that regulation of MKP-1, which is known to dephosphorylate ERK-1/2,18 was dependent on Nox4. Overexpression of Nox4 is associated with a parallel increase in MKP-1 expression, resulting in insulin-mediated differentiation of preadipocytes (Figure). Taken together, this study importantly links Nox4-derived H2O2 to the differentiation of preadipocytes into adipocytes, even in the absence of insulin. Given the high prevalence of vascular and renal disease in obese patients,1 the present work raises the question whether Nox4 also levels modulate adipose tissue homeostasis in vivo.
|
Interestingly, the authors also report difficulties associated with RNA silencing, as they found that although nine probes were claimed to be specific by the manufacturer, several of the siRNA used also blocked other Nox isoforms, and only 1 out of 9 was specific for Nox4.16 According to siRNA manufacturers, siRNA technology is not entirely specific for the genes of interest, and standard siRNA may silence multiple genes unrelated to the gene of interest or have unspecific effects.16,19–21 New developments in RNA silencing may help to reduce this problem. Therefore, the work by Schröder et al is one more piece adding to the puzzle that seemingly specific new technology often comes with unexpected limitations.20,21
Nox4-derived reactive oxygen species have been implicated in coronary heart disease, hypertension, and renal failure, mainly because of the detrimental effects of excessively high levels of reactive oxygen species.22–24 Whether known activators of Nox4, such as the renin–angiotensin system17 which becomes activated during obesity,25 also cause preadipocytes to differentiate and thereby stimulate obesity development is a tempting hypothesis and would by supported by the work of Schröder et al.16 One therefore might ask the question whether drugs known to inhibit NADPH oxidase such as statins or angiotensin receptor blockers affect preadipocyte differentiation and proliferation. The latter has been shown by Mori and associates,26 and it appears that the work by Schröder et al has succeeded to provide us with one important missing link that might explain these previous observations.26
Despite all the advances in research we should keep in mind that abdominal obesity, the visually apparent consequence of visceral preadipocyte differentiation, continues to be a major health issue around the world affecting both adults and children.1–6 Should we fail to get radical about obesity in time, today’s children might not live up to our expectations.27
 |
Acknowledgments |
|---|
The authors thank Dr Matthias Saur for critical reading of the manuscript.
Sources of Funding
This work was supported by grants of the Swiss National Science Foundation (3200-108258/1 and K-33KO122504/1), and by the University of Zurich.
Disclosures
None.
|
References |
|---|
 Top References |
|---|
1. Barton M, Furrer J. Cardiovascular consequences of the obesity pandemic: need for action. Expert Opin Investig Drugs. 2003; 12: 1757–1759.[CrossRef][Medline] [Order article via Infotrieve]
2. Lakka HM, Lakka TA, Tuomilehto J, Salonen JT. Abdominal obesity is associated with increased risk of acute coronary events in men. Eur Heart J. 2002; 23: 706–713.
3. Lakka TA, Lakka HM, Salonen R, Kaplan GA, Salonen JT. Abdominal obesity is associated with accelerated progression of carotid atherosclerosis in men. Atherosclerosis. 2001; 154: 497–504.[CrossRef][Medline] [Order article via Infotrieve]
4. Sorof J, Daniels S. Obesity hypertension in children: a problem of epidemic proportions. Hypertension. 2002; 40: 441–447.
5. Kosti RI, Panagiotakos DB. The epidemic of obesity in children and adolescents in the world. Cent Eur J Public Health. 2006; 14: 151–159.[Medline] [Order article via Infotrieve]
6. Jackson-Leach R, Lobstein T. Estimated burden of paediatric obesity and co-morbidities in Europe. Part 1. The increase in the prevalence of child obesity in Europe is itself increasing. Int J Pediatr Obes. 2006; 1: 26–32.[CrossRef][Medline] [Order article via Infotrieve]
7. Finkelstein EA, Fiebelkorn IC, Wang G. State-level estimates of annual medical expenditures attributable to obesity. Obes Res. 2004; 12: 18–24.[Medline] [Order article via Infotrieve]
8. Finkelstein EA, Fiebelkorn IC, Wang G. National medical spending attributable to overweight and obesity: how much, and who’s paying? Health Aff (Millwood). 2003; Suppl Web Exclusives: W3–219–226.
9. Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest. 2003; 112: 1785–1788.[CrossRef][Medline] [Order article via Infotrieve]
10. Porras A, Alvarez AM, Valladares A, Benito M. p42/p44 mitogen-activated protein kinases activation is required for the insulin-like growth factor-I/insulin induced proliferation, but inhibits differentiation, in rat fetal brown adipocytes. Mol Endocrinol. 1998; 12: 825–834.
11. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004; 114: 1752–1761.[CrossRef][Medline] [Order article via Infotrieve]
12. Kahler J, Mendel S, Weckmuller J, Orzechowski HD, Mittmann C, Koster R, Paul M, Meinertz T, Munzel T. Oxidative stress increases synthesis of big endothelin-1 by activation of the endothelin-1 promoter. J Mol Cell Cardiol. 2000; 32: 1429–1437.[CrossRef][Medline] [Order article via Infotrieve]
13. Bhattacharya I, Ullrich A. Endothelin-1 inhibits adipogenesis: role of phosphorylation of Akt and ERK1/2. FEBS Lett. 2006; 580: 5765–5771.[CrossRef][Medline] [Order article via Infotrieve]
14. Mouche S, Mkaddem SB, Wang W, Katic M, Tseng YH, Carnesecchi S, Steger K, Foti M, Meier CA, Muzzin P, Kahn CR, Ogier-Denis E, Szanto I. Reduced expression of the NADPH oxidase NOX4 is a hallmark of adipocyte differentiation. Biochim Biophys Acta. 2007; 1773: 1015–1027.[Medline] [Order article via Infotrieve]
15. Mahadev K, Motoshima H, Wu X, Ruddy JM, Arnold RS, Cheng G, Lambeth JD, Goldstein BJ. The NAD(P)H oxidase homolog Nox4 modulates insulin-stimulated generation of H2O2 and plays an integral role in insulin signal transduction. Mol Cell Biol. 2004; 24: 1844–1854.
16. Schroder K, Wandzioch K, Helmcke I. Brandes RP. Nox4 Acts as a switch between differentiation and proliferation in preadipocytes. Arterioscler Thromb Vasc Biol. 2009; 29: 239–245.
17. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 2007; 87: 245–313.
18. Sun H, Charles CH, Lau LF, Tonks NK. MKP-1 (3CH134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates MAP kinase in vivo. Cell. 1993; 75: 487–493.[CrossRef][Medline] [Order article via Infotrieve]
19. Svoboda P. Off-targeting and other non-specific effects of RNAi experiments in mammalian cells. Curr Opin Mol Ther. 2007; 9: 248–257.[Medline] [Order article via Infotrieve]
20. Kleinman ME, Yamada K, Takeda A, Chandrasekaran V, Nozaki M, Baffi JZ, Albuquerque RJ, Yamasaki S, Itaya M, Pan Y, Appukuttan B, Gibbs D, Yang Z, Kariko K, Ambati BK, Wilgus TA, DiPietro LA, Sakurai E, Zhang K, Smith JR, Taylor EW, Ambati J. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature. 2008; 452: 591–597.[CrossRef][Medline] [Order article via Infotrieve]
21. Kalluri R, Kanasaki K. RNA interference: generic block on angiogenesis. Nature. 2008; 452: 543–545.[CrossRef][Medline] [Order article via Infotrieve]
22. Griendling KK, Harrison DG. Out, damned dot: studies of the NADPH oxidase in atherosclerosis. J Clin Invest. 2001; 108: 1423–1424.[CrossRef][Medline] [Order article via Infotrieve]
23. Paravicini TM, Touyz RM. NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. Diabetes Care. 2008; 31 Suppl 2: S170–S180.
24. Sorescu D, Weiss D, Lassegue B, Clempus RE, Szocs K, Sorescu GP, Valppu L, Quinn MT, Lambeth JD, Vega JD, Taylor WR, Griendling KK. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation. 2002; 105: 1429–1435.
25. Barton M, Carmona R, Morawietz H, d'Uscio LV, Goettsch W, Hillen H, Haudenschild CC, Krieger JE, Munter K, Lattmann T, Luscher TF, Shaw S. Obesity is associated with tissue-specific activation of renal angiotensin-converting enzyme in vivo: evidence for a regulatory role of endothelin. Hypertension. 2000; 35: 329–336.
26. Mori Y, Itoh Y, Tajima N. Angiotensin II receptor blockers downsize andiocytes in spontaneously type 2 diabetic rats with visceral fat obesity. Am J Hypertens. 2007; 20: 431–436.[CrossRef][Medline] [Order article via Infotrieve]
27. Olshansky SJ, Passaro DJ, Hershow RC, Layden J, Carnes BA, Brody J, Hayflick L, Butler RN, Allison DB, Ludwig DS. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med. 2005; 352: 1138–1145.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||